KRW 9750.0
(-0.41%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 13.64 Billion KRW | 636.74% |
2022 | 1.85 Billion KRW | -93.56% |
2021 | 28.73 Billion KRW | 91.96% |
2020 | 14.97 Billion KRW | 387.67% |
2019 | 3.07 Billion KRW | -79.32% |
2018 | 14.84 Billion KRW | 1000.04% |
2017 | 1.34 Billion KRW | 0.0% |
2016 | - KRW | 0.0% |
2015 | - KRW | 0.0% |
2014 | - KRW | -100.0% |
2013 | 3.95 Billion KRW | 1878.0% |
2012 | 200 Million KRW | 0.0% |
2011 | - KRW | 0.0% |
2010 | - KRW | -100.0% |
2009 | 3.75 Billion KRW | -57.14% |
2008 | 8.75 Billion KRW | -50.54% |
2007 | 17.69 Billion KRW | -27.62% |
2006 | 24.44 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 14.11 Billion KRW | 3.51% |
2024 Q2 | 66.7 Million KRW | -99.53% |
2023 FY | 13.64 Billion KRW | 636.74% |
2023 Q3 | 21.4 Billion KRW | 4.41% |
2023 Q2 | 20.5 Billion KRW | 753.41% |
2023 Q4 | 13.64 Billion KRW | -36.28% |
2023 Q1 | 2.4 Billion KRW | 29.76% |
2022 Q4 | 1.85 Billion KRW | -36.08% |
2022 FY | 1.85 Billion KRW | -93.56% |
2022 Q3 | 2.89 Billion KRW | -28.97% |
2022 Q2 | 4.07 Billion KRW | -86.29% |
2022 Q1 | 29.75 Billion KRW | 3.54% |
2021 FY | 28.73 Billion KRW | 91.96% |
2021 Q2 | 28.78 Billion KRW | 91.84% |
2021 Q3 | 29.43 Billion KRW | 2.26% |
2021 Q4 | 28.73 Billion KRW | -2.36% |
2021 Q1 | 15 Billion KRW | 0.21% |
2020 Q2 | 14.95 Billion KRW | 151.88% |
2020 FY | 14.97 Billion KRW | 387.67% |
2020 Q3 | 14.99 Billion KRW | 0.24% |
2020 Q1 | 5.93 Billion KRW | 93.44% |
2020 Q4 | 14.97 Billion KRW | -0.15% |
2019 Q4 | 3.07 Billion KRW | -82.84% |
2019 Q3 | 17.88 Billion KRW | 13.49% |
2019 FY | 3.07 Billion KRW | -79.32% |
2019 Q1 | 15.99 Billion KRW | 7.74% |
2019 Q2 | 15.76 Billion KRW | -1.45% |
2018 Q2 | 17.17 Billion KRW | 1211.37% |
2018 FY | 14.84 Billion KRW | 1000.04% |
2018 Q4 | 14.84 Billion KRW | -14.37% |
2018 Q3 | 17.33 Billion KRW | 0.92% |
2018 Q1 | 1.3 Billion KRW | 0.0% |
2017 FY | 1.34 Billion KRW | 0.0% |
2017 Q1 | - KRW | 0.0% |
2017 Q2 | - KRW | 0.0% |
2017 Q3 | - KRW | 0.0% |
2016 Q4 | - KRW | 0.0% |
2016 Q3 | - KRW | 0.0% |
2016 Q2 | - KRW | 0.0% |
2016 Q1 | - KRW | -100.0% |
2016 FY | - KRW | 0.0% |
2015 Q1 | - KRW | -100.0% |
2015 FY | - KRW | 0.0% |
2015 Q4 | 250 Million KRW | 0.0% |
2015 Q3 | - KRW | 0.0% |
2015 Q2 | - KRW | 0.0% |
2014 Q4 | 301.26 Million KRW | -81.57% |
2014 Q3 | 1.63 Billion KRW | -59.3% |
2014 Q2 | 4.01 Billion KRW | 1.51% |
2014 Q1 | 3.95 Billion KRW | -42.7% |
2014 FY | - KRW | -100.0% |
2013 Q3 | 2.96 Billion KRW | 1.3% |
2013 Q2 | 2.93 Billion KRW | 1365.22% |
2013 FY | 3.95 Billion KRW | 1878.0% |
2013 Q1 | 200 Million KRW | 0.0% |
2013 Q4 | 6.9 Billion KRW | 132.59% |
2012 FY | 200 Million KRW | 0.0% |
2011 Q4 | - KRW | 0.0% |
2011 Q2 | - KRW | 0.0% |
2011 Q3 | - KRW | 0.0% |
2011 Q1 | - KRW | -100.0% |
2011 FY | - KRW | 0.0% |
2010 Q3 | 1.25 Billion KRW | -66.67% |
2010 Q2 | 3.75 Billion KRW | 0.0% |
2010 Q1 | 3.75 Billion KRW | -25.0% |
2010 Q4 | 1.25 Billion KRW | 0.0% |
2010 FY | - KRW | -100.0% |
2009 Q4 | 5 Billion KRW | -20.0% |
2009 Q2 | 7.5 Billion KRW | -14.29% |
2009 Q3 | 6.25 Billion KRW | -16.67% |
2009 FY | 3.75 Billion KRW | -57.14% |
2009 Q1 | 8.75 Billion KRW | -30.71% |
2008 Q3 | 14.31 Billion KRW | -10.55% |
2008 Q1 | 17.69 Billion KRW | -8.71% |
2008 FY | 8.75 Billion KRW | -50.54% |
2008 Q4 | 12.62 Billion KRW | -11.79% |
2008 Q2 | 16 Billion KRW | -9.54% |
2007 Q2 | 22.75 Billion KRW | 0.0% |
2007 Q4 | 19.37 Billion KRW | -8.01% |
2007 Q3 | 21.06 Billion KRW | -7.42% |
2007 FY | 17.69 Billion KRW | -27.62% |
2006 FY | 24.44 Billion KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 93.25% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | 54.345% |
HANDOK Inc. | 123.78 Billion KRW | 88.98% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -2767.105% |
Yuhan Corporation | 60.23 Billion KRW | 77.355% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 91.58% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -13296.525% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 83.372% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -2210.661% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -125.455% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | 26.359% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -8.39% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | -753.118% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 0.0% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -11297.249% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 88.727% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | 57.375% |
JW Holdings Corporation | 20.65 Billion KRW | 33.97% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | 7.994% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | 54.533% |
JW Pharmaceutical Corporation | 30 Billion KRW | 54.533% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -6129.441% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -2249.115% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | 72.482% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -206.38% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | 0.0% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | 28.315% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 85.399% |
JW Pharmaceutical Corporation | 30 Billion KRW | 54.533% |
Yuhan Corporation | 60.23 Billion KRW | 77.355% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | -29.905% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | 66.219% |
Suheung Co., Ltd. | 74 Billion KRW | 81.569% |
JW Pharmaceutical Corporation | 30 Billion KRW | 54.533% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -227.363% |
Korea United Pharm Inc. | 10.96 Billion KRW | -24.425% |
CKD Bio Corp. | 69.43 Billion KRW | 80.355% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | 60.549% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | 15.425% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -4342.198% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -6129.441% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 81.085% |
Boryung Corporation | 151.7 Billion KRW | 91.009% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 82.63% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -125.455% |
JW Lifescience Corporation | 168 Million KRW | -8019.075% |